For Healthcare Professionals

A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors


About the study

The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) administered as a single agent and in combination with other study medications in people with solid tumors. This study is seeking participants who have an advanced solid tumor for which the available treatments are no longer effective in controlling their cancer. All participants in this study will receive PF-07799544. PF-07799544 comes as a tablet to take by mouth daily (initially 2 times per day, but this could change to once daily or another frequency). Depending on the part of the study, participants may also receive another study medicine. In the first part of the study, people with melanoma or other solid tumors may also receive encorafenib. Encorafenib comes as a capsule and is taken once per day. In the second part of the study, people with melanoma with a certain type of abnormal gene called "BRAF" will receive PF-07799544 with other study medicines (for example, PF-07284890 or PF-07799933). Participants may receive the study medicines for about 2 years. The study team will monitor how each participant is doing with the study treatment during regular visits at the study clinic.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Inclusion Criteria:

  1. Diagnosis of advanced/metastatic solid tumor including primary brain tumor for monotherapy phase 1a dose escalation
  2. Disease progressed during/following last prior treatment and no satisfactory alternative treatment options for monotherapy phase 1a dose escalation
  3. For Substudy A and B, histological or cytological diagnosis of advanced/metastatic melanoma
  4. For Substudy A and B, measurable disease by RECIST version 1.1
  5. For Substudy A, evidence of a BRAF V600 mutation in tumor tissue and/or blood
  6. For Substudy B, evidence of a BRAF V600 mutation or BRAF Class II alteration in tumor tissue and/or blood


Exclusion Criteria:

  1. Brain metastasis larger than 4 cm
  2. Systemic anti-cancer therapy or small molecule therapeutics ongoing at the start of study treatment.
  3. For participants who may get binimetinib on study, history or current evidence of retinal vein occlusion (RVO) or concurrent neuromuscular disorder associated with elevated creatine kinase (CK)
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Study’s details


Melanoma,Glioma,Thyroid Cancer,Non-Small Cell Lung Cancer,Malignant Neoplasms,Brain Neoplasms,Colorectal Cancer

Age (in years)



Phase 1

Participants needed


Est. Completion Date

Feb 26, 2027

Treatment type



Pfizer identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.